CoChat

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

Riddle, Matthew C., Henry, Robert R., Poon, Terri H., Zhang, Bei, Mac, Susanna M., Holcombe, John H., Kim, Dennis D., Maggs, David G. · 2006 · Diabetes/Metabolism Research and Reviews
Cited by 126

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background: In two placebo‐controlled 30‐week trials, treatment with exenatide reduced HbA 1c and body weight in patients with type 2 diabetes in the context of sulphonylurea (SU) or SU plus metformin (MET) as background treatment. This analysis examines the effects of 82 weeks of exenatide treatment for participants in these earlier 30‐week trials. Methods: Data were pooled from the two pivotal trials of exenatide added to SU or SU plus MET. Both 30‐week, placebo‐controlled trials of 5 µg or 10 µg exenatide b.i.d. were followed by 52‐week open‐label, uncontrolled extension studies in which all participants received 10 µg exenatide b.i.d. and continued prior oral therapies. This interim analysis includes data for 222 patients who completed 82 weeks of exenatide treatment (61% M, age 57 ± 10 y, weight 99 ± 21 kg, BMI 34 ± 6 kg/m 2, HbA 1c 8.4 ± 1.0% [mean ± SD]). Results: Reduction in HbA 1c from baseline to week 30 (−0.8 ± 0.1% and −1.0 ± 0.1% for 5 µg b.i.d. and 10 µg b.i.d., respectively [mean ± SE]) was sustained up to week 82 (−1.0 ± 0.1%). Of 207 patients with baseline HbA 1c > 7%, 44% achieved HbA 1c ≤ 7% at week 82. Reduction of body weight from baseline to week 30 (−1.4 ± 0.3 kg and −2.1 ± 0.3 kg for 5 µg b.i.d. and 10 µg b.i.d., respectively) was progressive up to week 82 (−4.0 ± 0.3 kg). The most frequent adverse events were nausea and hypoglycaemia, both generally mild to moderate in intensity. Conclusions: Exenatide added to maximally effective doses of SU or SU plus MET resulted in a sustained reduction in HbA 1c and a progressive reduction in weight over $\def\qdr#1#2{\begingroup\hbox{\raise0.3em\hbox{$\scriptstyle #1$}$\!{/}\!$\lower0.2em\hbox{$\scriptstyle #2$}}\endgroup}1\qdr{1}{2}$ years. Copyright © 2006 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.646

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 13

  1. 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
  2. 1998, Lancet, 352, 1557
  3. 10.1111/j.1600-051X.1988.tb01003.x · DOI · Paper page
  4. 10.1016/S0140-6736(05)77963-0 · DOI
  5. 10.1002/dmrr.478 · DOI · Paper page
  6. 10.2165/00024677-200302010-00004 · DOI
  7. 10.1016/j.regpep.2003.10.028 · DOI · Paper page
  8. 10.1007/BF00606420 · DOI
  9. 10.2337/diacare.17.10.1100 · DOI · Paper page
  10. 10.1016/S0168-8227(99)00002-9 · DOI · Paper page
  11. Campbell IW, 1994, One year comparative trial of metformin and glipizide in type 2 diabetes mellitus, Diabetes Metab, 20, 394
  12. 10.1152/ajpendo.2001.281.1.E155 · DOI · Paper page
  13. 10.1210/endo.141.6.7490 · doi:10.1210/endo.141.6.7490 · Paper page

Cited by

Metadata

Authors
Riddle, M. C., Henry, R. R., Poon, T. H., Zhang, B., Mac, S. M., Holcombe, J. H., Kim, D. D., & Maggs, D. G.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2006-04-24
Volume
22
Issue
6
Pages
483-491
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W1972204120
Cited by
126
References
8
FWCI
10.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.